Inhibitory effects of antisense oligodeoxynucleotide on expression of vascular endothelia growth factor by human...

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Solid tumor growth relies on angiogenesis, a process driven by vascular endothelial growth factor (VEGF).
• Inhibiting angiogenesis is a key strategy in cancer therapy, with VEGF gene suppression being a target.
• Antisense drugs and RNA interference aim to suppress tumor angiogenesis by targeting VEGF.

Purpose of the Study:

• To evaluate the efficacy of four antisense oligodeoxynucleotides (ASODN) in inhibiting VEGF expression for hepatocellular carcinoma (HCC) gene therapy.
• To compare the inhibitory effects of different ASODN sequences on VEGF mRNA and protein levels.

Main Methods:

• Four ASODN groups (A-Cap, A-AUG, A-UGA, A-Exon-3) were designed to block VEGF expression in HCC.
• VEGF mRNA levels were quantified using RT-PCR.
• VEGF protein levels were assessed via Western blot analysis.

Main Results:

• All four ASODN treatments significantly reduced VEGF mRNA levels, with A-Cap showing the greatest reduction (32+/-9%).
• VEGF protein levels were also significantly decreased by all ASODN treatments, with A-Cap achieving a 41+/-5% reduction.
• The ASODN targeting the Cap structure exhibited the strongest inhibitory effect on both VEGF mRNA and protein expression.

Conclusions:

• ASODN targeting the Cap structure is the most effective among the tested sequences for inhibiting VEGF expression in HCC.
• The inhibitory effects of ASODN on VEGF protein levels closely mirrored their effects on VEGF mRNA levels.
• These findings support the potential of ASODN-based gene therapy for targeting tumor angiogenesis in HCC.